Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 2:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 2,650 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Topical Clear all
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of DUR-928 Topical Solution in Subjects With Plaque Psoriasis

NCT03837743
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
DUR-928 Topical Solution, Vehicle Topical Solution
Drug
Lead sponsor
Durect
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
5
States / cities
San Diego, California • Miami, Florida • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2022 · Synced Oct 24, 2026, 2:20 PM EDT
Completed Phase 3 Interventional Results available

Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Dermatitis

NCT05142774
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tapinarof cream, 1%
Drug
Lead sponsor
Organon and Co
Industry
Eligibility
2 Years and older
Enrollment
728 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
102
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 88 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Oct 24, 2026, 2:20 PM EDT
Completed Phase 2 Interventional

Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel

NCT00239135
View directory record Official record
Conditions
Keratosis
Interventions
PEP005
Drug
Lead sponsor
Peplin
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Tyler, Texas
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 24, 2026, 2:20 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of LEO 80185 Topical Suspension in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis

NCT01083758
View directory record Official record
Conditions
Scalp Psoriasis
Interventions
LEO 80185 (Taclonex® Scalp topical suspension/Xamiol® gel)
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
12 Years to 17 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
6
States / cities
San Diego, California • Jacksonville, Florida • Ormond Beach, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 24, 2026, 2:20 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension

NCT04285580
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
Bimatoprost SR, LUMIGAN
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
Dothan, Alabama • Newport Beach, California • Roswell, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Oct 24, 2026, 2:20 PM EDT
Terminated Phase 2 Interventional

ALA-PDT Versus Vehicle PDT for Treatment of AK and Reduction of New NMSC in Solid Organ Transplant Recipients

NCT00865878
View directory record Official record
Conditions
Actinic Keratoses, Skin Neoplasms
Interventions
Aminolevulinic Acid, Vehicle
Drug · Other
Lead sponsor
DUSA Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
7
States / cities
Irvine, California • San Francisco, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2011 · Synced Oct 24, 2026, 2:20 PM EDT
Completed Phase 2 Interventional Results available

Ruxolitinib Cream in the Treatment of Cutaneous Necrobiosis Lipoidica

NCT04492618
View directory record Official record
Conditions
Necrobiosis Lipoidica
Interventions
Ruxolitinib
Drug
Lead sponsor
Aaron R. Mangold
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 24, 2026, 2:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SM04755 Following Topical Administration to Healthy Subjects

NCT03229291
View directory record Official record
Conditions
Tendinopathy
Interventions
SM04755, Vehicle
Drug
Lead sponsor
Biosplice Therapeutics, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Oct 24, 2026, 2:20 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Systemic and Topical Antivirals for Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes

NCT03586284
View directory record Official record
Conditions
Cytomegalovirus Anterior Uveitis
Interventions
Valganciclovir Hydrochloride, Ganciclovir Sodium, Placebo Oral Tablet, Topical placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 24, 2026, 2:20 PM EDT
Not listed Phase 2 Interventional

Efficacy and Safety of PR022 Topical Gel to Treat Mild-to-Moderate Atopic Dermatitis

NCT03351777
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
PR022
Drug
Lead sponsor
Realm Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 21, 2017 · Synced Oct 24, 2026, 2:20 PM EDT
Completed Phase 4 Interventional

Reduction of Topical Anesthetic Time for Subcutaneous Port Access Using Ultrasound

NCT00126919
View directory record Official record
Conditions
Pain
Interventions
SonoPrep
Device
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
3 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 9, 2012 · Synced Oct 24, 2026, 2:20 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Lidocaine Patches Prior to Percutaneous Nerve Evaluation

NCT05783219
View directory record Official record
Conditions
Overactive Bladder, Urge Incontinence, Fecal Incontinence
Interventions
Lidocaine patch, Placebo
Drug · Other
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older · Female only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 24, 2026, 2:20 PM EDT
Completed Not applicable Interventional Results available

Hydrus Microstent for Refractory Open-Angle Glaucoma

NCT03267134
View directory record Official record
Conditions
Open-angle Glaucoma
Interventions
Hydrus Microstent, Ophthalmic surgery
Device · Procedure
Lead sponsor
Ivantis, Inc.
Industry
Eligibility
45 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
16
States / cities
Fayetteville, Arkansas • Sacramento, California • Fort Collins, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 24, 2026, 2:20 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study With Diltiazem Hydrochloride Cream to Treat Anal Fissures

NCT01690221
View directory record Official record
Conditions
Chronic Anal Fissures
Interventions
VEN 307, Placebo
Drug
Lead sponsor
Ventrus Biosciences, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
434 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
103
States / cities
Anniston, Alabama • Mobile, Alabama • Montgomery, Alabama + 85 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2014 · Synced Oct 24, 2026, 2:20 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety and Efficacy of BRM421 for Dry Eye Syndrome Treatment

NCT04343287
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
BRM421, Placebo
Drug
Lead sponsor
BRIM Biotechnology Inc.
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
4
States / cities
Newport Beach, California • Indianapolis, Indiana • Andover, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 24, 2026, 2:20 PM EDT
Withdrawn Not applicable Interventional

The Study on Bacterial Load Following Open-to-air Management in Burn Patients.

NCT04502914
View directory record Official record
Conditions
Burns, Infection Wound, Bacterial Infections
Interventions
Open-to-air strategy, Traditional closed-wound management
Procedure
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Jan 5, 2022 · Synced Oct 24, 2026, 2:20 PM EDT
Recruiting Phase 1 Interventional

A Study of Amicidin-β Topical Solution for Patients With Surgical or Traumatic Wound Infections

NCT07379684
View directory record Official record
Conditions
Surgical Wound Infection, Traumatic Wound Infection
Interventions
Amicidin-β topical solution - 15 mL, Amicidin-β topical solution - 50 mL, Standard of Care (SOC)
Drug
Lead sponsor
Macro Biologics, Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
5
States / cities
Torrance, California • Idaho Falls, Idaho • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 24, 2026, 2:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study on the Effects of Exogenous Testosterone on Threat Perception and Behavioral Avoidance

NCT01408498
View directory record Official record
Conditions
Testosterone's Effects on Threat Perception/Response
Interventions
Testosterone
Drug
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2012 · Synced Oct 24, 2026, 2:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Irritation and Sensitization Study of HP-5000 Topical System

NCT04882319
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
HP-5000 Topical Patch, HP-5000 Placebo Patch, Saline Patch
Drug
Lead sponsor
Noven Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Oct 24, 2026, 2:20 PM EDT
Completed Phase 2 Interventional

A One Year Open Label Study for the Treatment of Hypogonadism (Low Testosterone) in Men Who Have Completed ZA-203

NCT01386567
View directory record Official record
Conditions
Hypogonadism, Low Testosterone
Interventions
Androxal (enclomiphene citrate), Testim (topical testosterone)
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
21 Years to 65 Years · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
8
States / cities
Garden Grove, California • Sacramento, California • San Diego, California + 2 more
Source: ClinicalTrials.gov public record
Updated May 17, 2013 · Synced Oct 24, 2026, 2:20 PM EDT
Terminated Phase 2Phase 3 Interventional

Diclofenac Patch for Treatment of Mild to Moderate Ankle Sprain

NCT00640705
View directory record Official record
Conditions
Ankle Sprain
Interventions
diclofenac sodium, Matching placebo patch
Drug
Lead sponsor
Cerimon Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 4, 2008 · Synced Oct 24, 2026, 2:20 PM EDT
Recruiting Phase 4 Interventional

An Open Label Trial to Evaluate Efficacy and Safety of Roflumilast 0.3% Cream for Chronic Plaque and Nail Psoriasis

NCT07725822
View directory record Official record
Conditions
Chronic Plaque Psoriasis, Nail Psoriasis
Interventions
Roflumilast 0.3% topical cream
Drug
Lead sponsor
Modern Research Associates, PLLC
Other
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 24, 2026, 2:20 PM EDT
Completed Phase 2 Interventional

A Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hidradenitis Suppurativa

NCT07077902
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Topical roflumilast 0.3% foam
Drug
Lead sponsor
Tulane University
Other
Eligibility
18 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
Covington, Louisiana • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 24, 2026, 2:20 PM EDT
Withdrawn Phase 1 Interventional

The Role of Prostaglandins in the Progression of Diabetic Retinopathy

NCT01609881
View directory record Official record
Conditions
Inflammation
Interventions
Acuvail, Placebo
Drug · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 24, 2026, 2:20 PM EDT